Daily Junction.mobi portalNews · October 25, 2024 · Daily Junction Editorial Team · 9 min
Five-year survival rates for common cancers in the UK remain below the European average, with late diagnosis and delayed treatment identified as key factors. New community diagnostic centres and screening programmes aim to close the gap, but workforce shortages and waiting times continue to hamper progress.
UK cancer survival rates continue to lag behind European averages despite significant NHS investment in early detection and treatment, according to the latest CONCORD-4 global cancer survival study published in August 2024. Five-year survival rates for common cancers in England are 5-10 percentage points lower than the best-performing European countries, with lung cancer (14% vs 20% in Sweden), pancreatic cancer (7% vs 11% in Belgium), and stomach cancer (21% vs 30% in South Korea) showing particularly stark gaps. Late diagnosis is the primary factor—only 54% of cancers in England are diagnosed at stage 1 or 2 (early stages), compared to 60-65% in leading European countries like Denmark, Sweden, and the Netherlands. Cancer waiting times have deteriorated, with only 68% of patients starting treatment within 62 days of urgent GP referral in September 2024, against the 85% constitutional standard. Screening uptake has fallen, with breast cancer screening at 66% (target 70%) and bowel cancer screening at just 59% (target 60%). The NHS has invested £2.3 billion in community diagnostic centres to increase scanning capacity and reduce waits, but radiologist shortages (12% vacancy rate) and oncologist shortages (9% vacancy rate) continue to hamper progress.
The CONCORD-4 study, the world's largest cancer survival study covering 37.5 million patients in 71 countries, shows the UK has improved cancer survival over the past two decades but remains behind European leaders:
Five-year survival rates (England vs European best, 2015-2019 data):
The gap is widest for cancers where early detection is critical (lung, pancreatic, stomach) and narrower for cancers with established screening programmes (breast, bowel, cervical).
Cancer Research UK analysis attributes 5,000-10,000 avoidable deaths per year in the UK to the survival gap with European leaders—these are deaths that would not occur if UK survival rates matched the best in Europe.
Stage at diagnosis is the single most important predictor of survival. Cancer Research UK data shows:
Five-year survival by stage (average across all cancers):
In England, stage at diagnosis (2023 data):
This means 46% of cancers are diagnosed at stage 3 or 4 (advanced stages), compared to 35-40% in Denmark, Sweden, and the Netherlands.
Why does the UK diagnose cancers later?
1. Lower GP consultation rates: UK patients see GPs an average of 5 times per year, compared to 7-8 times in Germany and France. Fewer consultations mean fewer opportunities for early detection.
2. Diagnostic delays: Average wait for a CT or MRI scan in the NHS is 4-6 weeks, compared to 1-2 weeks in Germany and France. This delays diagnosis and allows cancers to progress.
3. Cultural factors: The British "stiff upper lip" culture means people are less likely to seek medical help for vague symptoms. A 2023 Cancer Research UK survey found 40% of people would delay seeing a GP about potential cancer symptoms due to embarrassment, not wanting to waste the GP's time, or fear of what they might find.
4. Screening uptake: Lower uptake of screening programmes (see below) means cancers that could be detected early are missed.
5. Awareness: Public awareness of cancer symptoms is lower in the UK than in some European countries. A 2024 Macmillan survey found only 55% of people could name three or more cancer warning signs.
NHS England cancer waiting time standards are:
Performance (September 2024):
All three standards have been missed every month since 2015, and performance has deteriorated since the pandemic. In 2019, 76% of patients started treatment within 62 days; by 2024, this had fallen to 68%.
Reasons for delays:
The impact of delays on survival is significant. A 2020 Lancet Oncology study found that each 4-week delay in starting cancer treatment increases mortality by 6-13% depending on cancer type.
The NHS offers three national cancer screening programmes:
1. Breast cancer screening:
2. Bowel cancer screening:
3. Cervical cancer screening:
Uptake has fallen for all three programmes since the pandemic, partly due to appointment backlogs and partly due to reduced public engagement. Inequalities are stark:
Ethnicity gaps: Screening uptake is lower among Black and Asian women than White women, partly due to language barriers, cultural factors, and lower trust in healthcare.
Impact: Cancer Research UK estimates that increasing screening uptake to 75% across all programmes would prevent 4,500 cancer deaths per year.
The NHS has invested £2.3 billion in community diagnostic centres (CDCs) since 2021, with 160 CDCs now operational across England. CDCs offer:
The aim is to increase diagnostic capacity and reduce waits by locating services in convenient community settings (high streets, shopping centres) with extended hours (evenings, weekends).
Impact so far:
However, radiologist shortages (12% vacancy rate) limit the impact. Scans are only useful if they are reported (interpreted) by radiologists, and reporting backlogs have increased. Artificial intelligence is being piloted to assist radiologists by flagging abnormalities, but is not yet in widespread use.
Cancer workforce shortages are a major constraint:
Macmillan Cancer Support estimates the NHS needs an additional 3,500 cancer specialists by 2029 to meet demand and deliver waiting time standards.
Training is a constraint: it takes 13 years to train a consultant oncologist (5 years medical school, 2 years foundation, 6 years specialty training), meaning workforce expansion is slow.
Retention is also a problem: 30% of oncologists plan to retire or leave the NHS within 5 years, according to a 2024 Royal College of Radiologists survey, citing burnout, workload, and pay.
Several initiatives show promise:
![[View image]](/img/cancer-survival-rates-uk-lag-europe.jpg){kind=link}